Welcome to our dedicated page for Beigene SEC filings (Ticker: BEIGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Beigene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Beigene's regulatory disclosures and financial reporting.
John Oyler, Chief Executive Officer and Director of BeOne Medicines Ltd. (ONC), reported sales of American Depositary Shares on 09/16/2025 under a Rule 10b5-1 trading plan adopted on March 12, 2025. The Form 4 lists six sale transactions totaling 28,203 ADS at weighted-average prices ranging approximately from $323.61 to $327.78 (footnotes provide per-transaction ranges). Each ADS represents 13 ordinary shares. The filing shows multiple pools of ordinary shares held directly or indirectly through trusts and entities, with the reporting person disclaiming beneficial ownership of certain holdings. The form is signed by an attorney-in-fact on behalf of the reporting person.
BeOne Medicines Ltd. (BEIGF) filed a Form 144 notifying a proposed sale of 1,204 ADS expected to be sold on September 16, 2025 on NASDAQ with an aggregate market value of $400,053.08. The shares were originally acquired as founders' shares on November 24, 2010. The filing also discloses multiple Rule 10b5-1 sales during the past three months by related parties, including John Oyler and the Pan-Oyler Foundation, with recent individual sales on 07/09/2025 (27,802 ADS, $7,044,590.31) and other sales in June–July 2025 totaling several million dollars in gross proceeds. The filer affirms no undisclosed material adverse information and references Rule 10b5-1 plan representation.
BeOne Medicines Ltd. (BEIGF) insider filing shows a proposed sale of 27,803 ADS through Morgan Stanley Smith Barney, with an aggregate market value of $9,238,102.81 and approximately 54,564,278 ADS outstanding. The securities were acquired as Restricted Stock Units on 04/30/2022. The filer reported multiple Rule 10b5-1 sales in the past three months: 27,802 ADS on 07/09/2025 for $7,044,590.31; 1,661 ADS on 07/08/2025 for $406,520.95; 3,174 ADS on 06/23/2025 for $830,359.98; and 1,460 ADS on 06/17/2025 for $374,473.21, totaling 34,097 ADS sold for $8,655,944.45. The notice states the seller represents no undisclosed material adverse information and references reliance on Rule 10b5-1 where applicable.
